S
Sharon Mavroukakis
Researcher at Stanford University
Publications - 56
Citations - 15328
Sharon Mavroukakis is an academic researcher from Stanford University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 24, co-authored 38 publications receiving 14029 citations. Previous affiliations of Sharon Mavroukakis include National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley,John R. Wunderlich,Paul F. Robbins,James Chih-Hsin Yang,Patrick Hwu,Douglas J. Schwartzentruber,Suzanne L. Topalian,Richard M. Sherry,Nicholas P. Restifo,Amy M. Hubicki,Michael R. Robinson,Mark Raffeld,Paul H. Duray,Claudia A. Seipp,Linda Rogers-Freezer,Kathleen E. Morton,Sharon Mavroukakis,Donald E. White,Steven A. Rosenberg +18 more
TL;DR: The adoptive transfer of highly selected tumor-reactive T cells directed against overexpressed self-derived differentiation antigens after a nonmyeloablative conditioning regimen resulted in the persistent clonal repopulation of T cells in cancer patients, leading to regression of the patients' metastatic melanoma as well as to the onset of autoimmune melanocyte destruction.
Journal ArticleDOI
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan,Mark E. Dudley,John R. Wunderlich,Michael S. Hughes,James Chih-Hsin Yang,Richard M. Sherry,Richard E. Royal,Suzanne L. Topalian,Udai S. Kammula,Nicholas P. Restifo,Zhili Zheng,Azam V. Nahvi,Christiaan R. de Vries,Linda Rogers-Freezer,Sharon Mavroukakis,Steven A. Rosenberg +15 more
TL;DR: The ability to specifically confer tumor recognition by autologous lymphocytes from peripheral blood by using a retrovirus that encodes a T cell receptor is reported.
Journal ArticleDOI
Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
Mark E. Dudley,John R. Wunderlich,James Chih-Hsin Yang,Richard M. Sherry,Suzanne L. Topalian,Nicholas P. Restifo,Richard E. Royal,Udai S. Kammula,Donald E. White,Sharon Mavroukakis,Linda J. Rogers,Gerald J. Gracia,Stephanie Jones,David P. Mangiameli,Michelle M. Pelletier,Juan Gea-Banacloche,Michael R. Robinson,David Berman,Armando C. Filie,Andrea Abati,Steven A. Rosenberg +20 more
TL;DR: Lymphodepleting chemotherapy followed by the transfer of highly avid antitumor lymphocytes can mediate significant tumor regression in heavily pretreated patients with IL-2 refractory metastatic melanoma.
Journal ArticleDOI
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Giao Q. Phan,James Chih-Hsin Yang,Richard M. Sherry,Patrick Hwu,Suzanne L. Topalian,Douglas J. Schwartzentruber,Nicholas P. Restifo,Leah R. Haworth,Claudia A. Seipp,Linda J. Freezer,Kathleen E. Morton,Sharon Mavroukakis,Paul H. Duray,Seth M. Steinberg,James P. Allison,Thomas A. Davis,Steven A. Rosenberg +16 more
TL;DR: This study establishes CTLA-4 as an important molecule regulating tolerance to “self” antigens in humans and suggests a role for CTla-4 blockade in breaking tolerance to human cancer antIGens for cancer immunotherapy.
Journal ArticleDOI
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw,Michael H. Kershaw,Michael H. Kershaw,Jennifer A. Westwood,Jennifer A. Westwood,Linda L. Parker,Gang Wang,Gang Wang,Zelig Eshhar,Sharon Mavroukakis,Donald E. White,John R. Wunderlich,Silvana Canevari,Linda Rogers-Freezer,Clara C. Chen,James Chih-Hsin Yang,Steven A. Rosenberg,Patrick Hwu +17 more
TL;DR: Large numbers of gene-modified tumor-reactive T cells can be safely given to patients, but these cells do not persist in large numbers long term, and future studies need to employ strategies to extend T cell persistence.